The Northern Health Science Alliance (NHSA) has signed a memorandum of understanding (MOU) with the UK Israel Tech Hub (UKITH) to help bring new health and medtech innovations to the North of England.
At Biomed 2018, in Tel Aviv, Israel, head of corporate affairs for the NHSA, Suzanne Suzanne Ali-Hassan, signed the MOU with British ambassador to Israel, Dave Quarrey.
The initiative will support Israeli healthcare companies establishing research within the UK, in particular the North of England.
The NHSA will provide support to Israeli companies suggested by the UKITH to access UK clinical research areas in the North of England. The aim is to help companies build a business case for their innovations when entering the UK, helping them engage with health research professionals, health economic teams and clinical expertise for the development of their technology within the NHS.
The UKITH will support Israeli companies access and identify funding to secure partnerships within the UK clinical research environment in the North of England, as well as develop partnerships via the NHSA.
Ms Ali-Hassan said: “We’re thrilled to be signing this memorandum of understanding with the UK Israel Tech Hub which will open up the North of England to innovative and cutting-edge Israeli health technology.
“There are well over 1,400 life science and healthcare companies in Israel whose innovations have the potential to bring great benefits to the North’s hospitals and patient population.”
The NHSA brings together 15 million population, eight research intensive universities, eight NHS teaching hospitals and four academic health science networks across thee North of England.
Ambassador Quarrey said: “This is the latest sign of the deepening innovation links between our two countries. The agreement will further enable British researchers and patients to have access to the latest technology from Israel.
“And we hope even more Israeli medical companies will now look to the UK as a destination for their growth.”